Search
Canosimibe
go.drugbank.com/drugs/DB19723InvestigationalCanosimibe is a small molecule drug. … Canosimibe has a monoisotopic molecular weight of 809.43 Da.
Prezatide copper
go.drugbank.com/drugs/DB14683InvestigationalPrezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions [A19503]. Prezatide is used in cosmetic products for the skin and hair.
Torcetrapib
go.drugbank.com/drugs/DB06281InvestigationalTorcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination
Danvatirsen
go.drugbank.com/drugs/DB14825InvestigationalDanvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).
Tovinontrine
go.drugbank.com/drugs/DB16193InvestigationalTovinontrine is an orally administered, highly selective phosphodiesterase 9 (PDE9) small molecule inhibitor. … Tovinontrine is under investigation in clinical trial NCT04474314 (A Study of IMR-687 in Subjects With Sickle Cell Disease).
Synonyms: 6-((3S,4S)-4-METHYL-1-(2-PYRIMIDINYLMETHYL)-3-PYRROLIDINYL)-3-(TETRAHYDRO-2H-PYRAN-4-YL)IMIDAZO(1,5-A)PYRAZIN-8(7H)-ONE, 6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-oneTBX-3400
go.drugbank.com/drugs/DB17370InvestigationalTBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.
Zilebesiran
go.drugbank.com/drugs/DB18929InvestigationalZilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care
OC-1012
go.drugbank.com/drugs/DB05834ExperimentalOC-1012 is a compound which has emerged as a promising therapeutic agent for the treatment and prevention of mucositis, a serious side effect of chemotherapy and head and neck radiation therapy.
BMS-564929
go.drugbank.com/drugs/DB07286ExperimentalBMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM).